Simcere Pharmac Grp Stock Return On Equity
| S2P Stock | EUR 0.81 0.01 1.22% |
SIMCERE PHARMAC GRP fundamentals help investors to digest information that contributes to SIMCERE PHARMAC's financial success or failures. It also enables traders to predict the movement of SIMCERE Stock. The fundamental analysis module provides a way to measure SIMCERE PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SIMCERE PHARMAC stock.
SIMCERE |
SIMCERE PHARMAC GRP Company Return On Equity Analysis
SIMCERE PHARMAC's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current SIMCERE PHARMAC Return On Equity | 0.17 |
Most of SIMCERE PHARMAC's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SIMCERE PHARMAC GRP is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, SIMCERE PHARMAC GRP has a Return On Equity of 0.1701. This is 100.71% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The return on equity for all Germany stocks is 154.87% lower than that of the firm.
SIMCERE Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SIMCERE PHARMAC's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SIMCERE PHARMAC could also be used in its relative valuation, which is a method of valuing SIMCERE PHARMAC by comparing valuation metrics of similar companies.SIMCERE PHARMAC is rated second in return on equity category among its peers.
SIMCERE Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0344 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.1 % | |||
| Shares Outstanding | 2.66 B | |||
| Shares Owned By Insiders | 69.20 % | |||
| Shares Owned By Institutions | 4.70 % | |||
| Revenue | 5.58 B | |||
| Gross Profit | 3.92 B | |||
| EBITDA | 743.59 M | |||
| Book Value Per Share | 2.31 X | |||
| Earnings Per Share | 0.05 X | |||
| Number Of Employees | 6.54 K | |||
| Beta | 0.48 | |||
| Market Capitalization | 3.75 B | |||
| Annual Yield | 0.02 % | |||
| Last Dividend Paid | 0.15 |
About SIMCERE PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SIMCERE PHARMAC GRP's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SIMCERE PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SIMCERE PHARMAC GRP based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in SIMCERE Stock
SIMCERE PHARMAC financial ratios help investors to determine whether SIMCERE Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SIMCERE with respect to the benefits of owning SIMCERE PHARMAC security.